These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19049640)

  • 21. Distribution of six oncogenic types of human papillomavirus and type 16 integration analysis in Chinese women with cervical precancerous lesions and carcinomas.
    Liu SS; Tsang PC; Chan KY; Cheung AN; Chan KK; Leung RC; Ngan HY
    Tumour Biol; 2008; 29(2):105-13. PubMed ID: 18515988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions.
    Sasagawa T; Inoue M; Lehtinen M; Zhang W; Gschmeissner SE; Hajibagheri MA; Finch J; Crawford L
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):403-10. PubMed ID: 8807204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.
    Van Doorslaer K; Reimers LL; Studentsov YY; Einstein MH; Burk RD
    Gynecol Oncol; 2010 Feb; 116(2):208-12. PubMed ID: 19555999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-grade squamous intraepithelial lesion on Papanicolaou test: follow-up rates and stratification of risk for high-grade squamous intraepithelial lesion.
    Rufail M; Lew M; Pang J; Jing X; Heider A; Cantley RL
    J Am Soc Cytopathol; 2020; 9(4):258-265. PubMed ID: 32402830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of autoantibodies to survivin in cervical mucus from patients with human papillomavirus-associated cervical cancer and precursor lesions.
    Jimenez LG; Aguilar MC; Monroy OL; Cruz-Talonia F; Cruz RM; Huitron C; Rocha-Zavaleta L
    Autoimmunity; 2007 Feb; 40(1):66-72. PubMed ID: 17364499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing.
    Lehtinen M; Apter D; Dubin G; Kosunen E; Isaksson R; Korpivaara EL; Kyhä-Osterlund L; Lunnas T; Luostarinen T; Niemi L; Palmroth J; Petäjä T; Rekonen S; Salmivesi S; Siitari-Mattila M; Svartsjö S; Tuomivaara L; Vilkki M; Pukkala E; Paavonen J
    Int J STD AIDS; 2006 Aug; 17(8):517-21. PubMed ID: 16925896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions.
    Sasagawa T; Yamazaki H; Dong YZ; Satake S; Tateno M; Inoue M
    Int J Cancer; 1998 Feb; 75(4):529-35. PubMed ID: 9466652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia.
    Passmore JA; Marais DJ; Sampson C; Allan B; Parker N; Milner M; Denny L; Williamson AL
    J Med Virol; 2007 Sep; 79(9):1375-80. PubMed ID: 17607771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia.
    Matsumoto K; Yasugi T; Oki A; Fujii T; Nagata C; Sekiya S; Hoshiai H; Taketani Y; Kanda T; Kawana T; Yoshikawa H
    Cancer Lett; 2006 Jan; 231(2):309-13. PubMed ID: 16399232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age distribution of antibodies to human papillomavirus in children, women with cervical intraepithelial neoplasia and blood donors from South Africa.
    Marais D; Rose RC; Williamson AL
    J Med Virol; 1997 Feb; 51(2):126-31. PubMed ID: 9021543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study.
    Lang Kuhs KA; Lin SW; Hua X; Schiffman M; Burk RD; Rodriguez AC; Herrero R; Abnet CC; Freedman ND; Pinto LA; Hamm D; Robins H; Hildesheim A; Shi J; Safaeian M
    PLoS One; 2018; 13(1):e0178167. PubMed ID: 29385144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions.
    Rocha-Zavaleta L; Ambrosio JP; Mora-Garcia ML; Cruz-Talonia F; Hernandez-Montes J; Weiss-Steider B; Ortiz-Navarrete V; Monroy-Garcia A
    J Gen Virol; 2004 Sep; 85(Pt 9):2643-2650. PubMed ID: 15302958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.
    de Vos van Steenwijk PJ; Piersma SJ; Welters MJ; van der Hulst JM; Fleuren G; Hellebrekers BW; Kenter GG; van der Burg SH
    Clin Cancer Res; 2008 Nov; 14(22):7188-95. PubMed ID: 19010835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.
    Costa AP; Giraldo PC; Cobucci RN; Consolaro ML; Souza RP; Canário LB; Machado PR; Randall Martins R; Vieira Baptista P; Jr JE; Gonçalves AK
    Asian Pac J Cancer Prev; 2020 Sep; 21(9):2799-2804. PubMed ID: 32986383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].
    Fei M; Li J; Du J; You J; Zhang S; He W; Kang L; Zhao F; Qiao Y; Si Y; Fan X; Chen W
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 May; 35(5):514-8. PubMed ID: 25059358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.
    Bontkes HJ; de Gruijl TD; Walboomers JM; Schiller JT; Dillner J; Helmerhorst TJ; Verheijen RH; Scheper RJ; Meijer CJ
    J Gen Virol; 1999 Feb; 80 ( Pt 2)():409-417. PubMed ID: 10073701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution and attribution of high-risk human papillomavirus genotypes in cervical precancerous lesions in China.
    Wang W; An J; Song Y; Wang M; Huang M; Wu L
    Tumour Biol; 2017 Jul; 39(7):. PubMed ID: 28691644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia.
    Marais DJ; Rose RC; Lane C; Kay P; Nevin J; Denny L; Soeters R; Dehaeck CM; Williamson AL
    J Med Virol; 2000 Apr; 60(4):403-10. PubMed ID: 10686023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants.
    Revaz V; Zurbriggen R; Moser C; Schiller JT; Ponci F; Bobst M; Nardelli-Haefliger D
    Antiviral Res; 2007 Oct; 76(1):75-85. PubMed ID: 17617476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens.
    Elfgren K; Bistoletti P; Dillner L; Walboomers JM; Meijer CJ; Dillner J
    Am J Obstet Gynecol; 1996 Mar; 174(3):937-42. PubMed ID: 8633673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.